Open AccessPomegranate Juice does not Affect the Bioavailability of Cyclosporine in Healthy Thai Volunteers
Author(s) -
Wirin Anlamlert,
Pakawadee Sermsappasuk
Publication year - 2020
Publication title -
current clinical pharmacology
Language(s) - English
Resource type - Journals
eISSN - 2212-3938
pISSN - 1574-8847
DOI - 10.2174/1574884715666200110153125
Subject(s) - bioequivalence , bioavailability , cmax , medicine , pharmacokinetics , crossover study , pharmacology , dosing , adverse effect , oral administration , area under the curve , placebo , alternative medicine , pathology
It is still controversial whether pomegranate causes drug interactions. Pomegranate juice has been shown to inhibit CYP3A in-vitro and animal studies. The coadministration of pomegranate juice with cyclosporine, a narrow therapeutic drug that is the substrate of CYP3A, might lead to drug toxicity. The objective of this study is to investigate the effect of pomegranate juice on the pharmacokinetics of cyclosporine in healthy Thai volunteers.